Speaker illustration

Professor Philip Barter

University of New South Wales Sydney, Sydney (Australia)

Member of:

European Society of Cardiology

PCSK9 inhibition: science, outcomes and guidance (EBAC Accredited)

Event: ESC Congress 2018

Topic: Risk Factors and Prevention

Session type: Satellite Symposium

Thumbnail

State-of-the-art lipid treatment in coronary patients in 2017

Event: ESC CONGRESS 2017

Topic: Lipids (Epidemiology and Prevention)

Session type: Satellite Symposium

Thumbnail

This platform is supported by

logo Novo Nordisk